PT952148E - Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico - Google Patents
Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamicoInfo
- Publication number
- PT952148E PT952148E PT99302282T PT99302282T PT952148E PT 952148 E PT952148 E PT 952148E PT 99302282 T PT99302282 T PT 99302282T PT 99302282 T PT99302282 T PT 99302282T PT 952148 E PT952148 E PT 952148E
- Authority
- PT
- Portugal
- Prior art keywords
- cylobutil
- aryloxyarilsulfonylamino
- acid derivatives
- hydroxymic acid
- hydroxymic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8139298P | 1998-04-10 | 1998-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT952148E true PT952148E (pt) | 2004-09-30 |
Family
ID=22163854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99302282T PT952148E (pt) | 1998-04-10 | 1999-03-25 | Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico |
Country Status (10)
Country | Link |
---|---|
US (1) | US6156798A (pt) |
EP (1) | EP0952148B1 (pt) |
JP (1) | JP3626366B2 (pt) |
AT (1) | ATE266634T1 (pt) |
BR (1) | BR9901250A (pt) |
CA (1) | CA2268484C (pt) |
DE (1) | DE69917124T2 (pt) |
DK (1) | DK0952148T3 (pt) |
ES (1) | ES2220004T3 (pt) |
PT (1) | PT952148E (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1113862C (zh) * | 1997-02-03 | 2003-07-09 | 辉瑞产品公司 | 芳基磺酰氨基异羟肟酸衍生物 |
US20030225150A1 (en) * | 1997-04-21 | 2003-12-04 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia |
US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
US20030203956A1 (en) * | 1998-12-23 | 2003-10-30 | Masterrer Jaime L. | Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia |
US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US20030119895A1 (en) * | 1998-12-23 | 2003-06-26 | Pharmacia Corporation | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia |
DE60124684T2 (de) * | 2000-03-20 | 2007-09-13 | Merck Sharp & Dohme Ltd., Hoddesdon | Sulfonamido-substituierte verbrückte bicycloalkylderivative |
EP1191024A1 (en) * | 2000-09-22 | 2002-03-27 | Harald Tschesche | Thiadiazines and their use as inhibitors of metalloproteinases |
AU2002345792A1 (en) | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
AU2002349537A1 (en) * | 2001-11-29 | 2003-06-10 | Nippon Organon K.K. | Remedies for heart failure |
PE20030701A1 (es) * | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
EP1466899A4 (en) * | 2001-12-27 | 2010-01-06 | Dainippon Sumitomo Pharma Co | "HYDROXAMIC ACID DERIVATIVE AND MMP INHIBITOR CONTAINING THEM AS AN ACTIVE SUBSTANCE" |
JP2006502113A (ja) * | 2002-07-17 | 2006-01-19 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | マトリックス・メタロプロテイナーゼ−13アロステリック阻害剤と、セレコキシブ又はバルデコキシブでないシクロオキシゲナーゼ−2選択的阻害剤との複合体 |
BR0312727A (pt) * | 2002-07-17 | 2005-04-19 | Warner Lambert Co | Combinação de um inibidor alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib |
DE60331367D1 (de) | 2002-12-30 | 2010-04-01 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0326546D0 (en) * | 2003-11-14 | 2003-12-17 | Amersham Plc | Inhibitor imaging agents |
PL1786785T3 (pl) | 2004-08-26 | 2010-08-31 | Pfizer | Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe |
EP1998760A2 (en) * | 2006-03-30 | 2008-12-10 | James E. Summerton | Non peptidic molecules for detecting and treating tumors |
MX2009010621A (es) * | 2007-03-30 | 2009-12-11 | James E Summerton | Moleculas no petidicas, para detectar y tratar tumores. |
EP2119690A1 (en) * | 2008-05-14 | 2009-11-18 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Radiolabelled MMP selective compounds |
PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
PL331895A1 (en) * | 1996-08-23 | 1999-08-16 | Pfizer | Arylosulphonylamino derivatives of hydroxamic acid |
PT934259E (pt) * | 1996-10-16 | 2003-01-31 | American Cyanamid Co | Acidos beta-sulfonamido hidroxamicos como inibidores de metaloproteinases de matriz e de tace |
ATE263147T1 (de) * | 1997-08-08 | 2004-04-15 | Pfizer Prod Inc | Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren |
-
1999
- 1999-03-25 DE DE69917124T patent/DE69917124T2/de not_active Expired - Fee Related
- 1999-03-25 EP EP99302282A patent/EP0952148B1/en not_active Expired - Lifetime
- 1999-03-25 DK DK99302282T patent/DK0952148T3/da active
- 1999-03-25 ES ES99302282T patent/ES2220004T3/es not_active Expired - Lifetime
- 1999-03-25 PT PT99302282T patent/PT952148E/pt unknown
- 1999-03-25 AT AT99302282T patent/ATE266634T1/de not_active IP Right Cessation
- 1999-04-08 CA CA002268484A patent/CA2268484C/en not_active Expired - Fee Related
- 1999-04-09 JP JP10248699A patent/JP3626366B2/ja not_active Expired - Fee Related
- 1999-04-09 US US09/290,023 patent/US6156798A/en not_active Expired - Fee Related
- 1999-04-09 BR BR9901250-2A patent/BR9901250A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP3626366B2 (ja) | 2005-03-09 |
EP0952148B1 (en) | 2004-05-12 |
BR9901250A (pt) | 2000-05-16 |
DE69917124T2 (de) | 2005-05-12 |
US6156798A (en) | 2000-12-05 |
CA2268484C (en) | 2006-02-07 |
EP0952148A1 (en) | 1999-10-27 |
ATE266634T1 (de) | 2004-05-15 |
ES2220004T3 (es) | 2004-12-01 |
JPH11322705A (ja) | 1999-11-24 |
DE69917124D1 (de) | 2004-06-17 |
CA2268484A1 (en) | 1999-10-10 |
DK0952148T3 (da) | 2004-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT952148E (pt) | Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico | |
MY120235A (en) | Aryloxyarylsulfonylamino hydroxamic acid derivatives | |
NO941662D0 (no) | Benzofuranyl- og -tiofenyl-alkankarboksylsyrederivater | |
GB9801690D0 (en) | Therapeutic agents | |
NO940038D0 (no) | Arylsulfonamido-substituerte hydrokamsyrer | |
NO20002440L (no) | Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet | |
DE69915004D1 (de) | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate | |
ES2151156T3 (es) | Derivados de acidos n-(aroil)glicina hidroxamicos y compuestos relacionados. | |
FI902555A0 (fi) | Diarylstyrylkinolindisyror. | |
DE69331171D1 (de) | Chinolin und Chinazolin Derivate zur Behandlung von Arthritis | |
ATE280767T1 (de) | Antidiabetische thiazolidindione und ihre herstellung | |
DK0652208T3 (da) | Phenylalkan(en)syrer | |
FI972074A0 (fi) | Akrylamidderivat och foerfarande foer framstaellning daerav | |
ATE224361T1 (de) | Pestizide | |
ID26210A (id) | Proses pemurnian turunan sefalosporin | |
MX9306666A (es) | Nuevas azetidinonas substituidas como agentes antiinflamatorios y antidegenerativos. | |
BR0013751A (pt) | Processo para produção de derivados de ácido naftiridina-3-carboxìlico | |
ES2111920T3 (es) | Clatratos de agua de piperazinilpiridinas. | |
ECSP982620A (es) | Derivados de acidos ariloxiarilsulfonilamino hidroxamicos |